Truist downgraded OrthoPediatrics to Hold from Buy with a price target of $31, down from $39. The analyst has less confidence in estimate upside “which makes it hard to argue for a higher multiple.” The firm expects OrthoPediatrics’ core implant growth to continue to decelerate in 2024. It thinks the stock’s valuation fairly reflects the company’s’ growth potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics sees FY24 revenue $197M-$200M, consensus $177.7M
- OrthoPediatrics reports preliminary FY23 revenue $148.7M, consensus $148.88M
- OrthoPediatrics reports preliminary Q4 revenue $37.6M, consensus $37.77M
- OrthoPediatrics announces acquisition of Boston Orthotics & Prosthetics
- OrthoPediatrics Corp. Announces Preliminary Unaudited Financial Highlights for the Fourth Quarter & Full Year 2023
